| Theme | Therapeutic strategy for ulcerative colitis ; from standard to up-to-date | |
|---|---|---|
| Title | New drugs for the treatment of inflammatory bowel disease | |
| Publish Date | 2011/05 | |
| Author | Kaoru Yokoyama | Department of Gastroenterology, Kitasato University East Hospital |
| [ Summary ] | New drugs for the treatment of inflammatory bowel disease have been aggressively developed and studied clinically in Western countries and Japan. Promising drugs currently in clinical trails in Japan include 5-aminosalicylic acid preparations (AJG501 and MD-0901). In Western countries, drugs being developed for the treatment of ulcerative colitis include anti-tumor necrosis factor-α antibody preparations (adalimumab, golimumab), as well as anti-α4α7 integrin monoclonal antibodies (vedolizumab [MLN0002]) and α4α7 /α4α1 integrin adhesion inhibitors (AJM300). These latter drugs are expected to be effective in cases that are refractory to anti-tumor necrosis factor-α antibody preparations. Therapy best suited to individual patients should be selected after understanding the characteristics and side effects of newly developed drugs. | |